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INTRODUCTION
Biotinidase deficiency (OMIM 253260) is an autosomal
recessive metabolic disorder with an estimated global
incidence of 1:60,000 newborns.1 Most individuals with
untreated biotinidase deficiency (BD) show progressive
clinical features, including neurological abnormalities
such as seizures, hypotonia, ataxia, developmental
delay, sensorineural hearing impairment and optic
atrophy.2 BD is treated with 5 – 20 mg of biotin daily
independent of age.3 All symptomatic children show
clinical improvement within days to weeks,4 except for
visual abnormalities, hearing loss and developmental
delay, which are usually irreversible.5
In Pakistan, patients with BD are almost never
diagnosed early and often remain misdiagnosed. We
present two families with 4 children diagnosed as BD
and their follow-up. Family 2 highlights the importance of
first degree relatives screening for BD once a proband is
diagnosed as having BD.
CASE REPORT
Patient 1: This boy was born as the third child to first-
cousins parents at full-term after an uneventful
pregnancy and delivery. At the age of 3 years and 4
months, he developed conjunctivitis followed by ataxia
and a tendency to fall while walking with significant
thinning of scalp hair and loss of eye lashes and eye
brows. In addition, scaly and erythematous skin rashes
in the perioral, periorbital, periungual area and buttocks
developed. A day before admission to our hospital, he
developed tachypnea and stridor, which progressed to
severe respiratory distress. The main biochemical
laboratory evaluation showed metabolic acidosis
(pH 7.2, BE -12), raised lactate 4.3 mmol/L (normal
< 2 mmol/L), ketonuria (+2); serum ammonia 36 µmol/L
(normal range: 50 – 80 µmol/L), liver and renal functions
were normal.
Patient 2: This girl was born as first child of first-cousin
once removed parents at full-term after an uneventful
pregnancy. She attained normal developmental
milestones time till 18 months of age when she
developed high grade fever and seizure. CSF bio-
chemistry and culture was normal. At discharge, she
was grossly hypotonic and had lost all her motor mile
stones. Subsequently, the physician at that time started
her on oral biotin 10 mg twice daily without any
investigation or diagnosis. Mother reported that she
improved substantially on biotin over 3 – 4 months
duration and regained neck holding and sitting. She
started walking with support at 3 years. Family was not
compliant to the regular use of oral biotin. Whenever oral
biotin intake was interrupted, she would develop total
alopecia including loss of eyebrows and eyelashes,
which would recover within weeks of resuming oral
biotin. She was 16 years old and her mother reported
her strong refusal to visit hospital. She was seen in
metabolic clinic only once at the age of 16 years and
was mobile using crutches. She refused any kind of
investigation. The only laboratory investigation done was
dried blood spots for biotinidase assay. We could not
carry out visual evoked potential study (VEP) or
brainstem auditory evoked potential (BAEP).
Patient 3: Patient 3 is the sister to patient 2. She was
born as the second child of the family at full-term
uneventful pregnancy and delivery. Her early childhood
including development was normal. She started to lose
scalp hair first at the age of 121⁄4 years, which progressed
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to total alopecia including loss of eyelashes and
eyebrows by 121⁄2 years. She faced visual difficulty in
reading by 123⁄4 years and became ataxic. Symptoms
progressed over next 3 months. She was seen at
metabolic clinic at the age of 13 years. She was wheel
chair bound and had left school because of poor vision
and alopecia. Her skin examination showed scaly and
erythematous rashes in the perioral, periorbital and
periungual area. Focused laboratory investigation
showed plasma lactate 3.8 mmol/L and optic pathways
dysfunction predominantly demyelinating in nature on
VEP and normal BAEP.
Patient 4: Patient 4 is the youngest brother of patients 2
and 3. He was born at full-term uneventful pregnancy
and delivery. His early childhood including development
was normal. His symptoms started at 71⁄2 years of age
with skin rashes in the perioral, periorbital, periungual
area, buttock, oral ulcers and thinning of scalp hair. At
the same time he complained of poor vision and became
ataxic. He was seen in metabolic clinic at the age of 81⁄2
years. At that time he had total alopecia including loss of
eyelashes and eye brows. He was able to walk only with
support. Focused laboratory investigations showed
plasma lactate 4.2 mmol/L; VEP showed optic pathways
dysfunction predominantly demyelinating in nature.
BAEP was normal.
Clinical and biochemical features of patients are
summarized in Table I. Dried blood spots for biotinidase
activity of all 4 patients were sent to NSW Biochemical
Genetic Services at New Children's Hospital, Adelaide,
Australia, where biotinidase activity was determined with
a semiquantitative colorimeteric method using N-
biotinyl-p-aminobenzoic acid as substrate. Absent BD
activity was found in all 4 patients, so all of them were
diagnosed as profound BD.
Patient 1 was started on oral biotin 20 mg/day initially.
He showed clinical and biochemical improvement within
2 days. His skin rash disappeared along with improve-
ment of metabolic acidosis, normalization of lactic
acidemia and ketonuria. But his ataxia did not improve,
therefore; oral biotin was increased to 30 mg/day. He
responded to increased dose and was ambulatory
within 3 days of increased dose of biotin. Growth of
eyebrows, eye lashes and scalp hair was seen by the
end of 3 weeks. Photographs of patient 1, 3 and 4 are
shown in Figure 1. Patient 2, 3 and 4 were treated with
oral biotin 20 mg/day. Most symptoms disappeared
1 – 3 weeks after the initiation of treatment. For patient
3 and 4, skin rashes disappeared within first week.
Growth of eyelashes, eyebrows and scalp hair was seen
by second week of treatment. Patient 4 was walking
independently by the end of third week. Independent
ambulation was seen in patient 3 by the end of 5th week.
In Patient 3, vision also improved significantly as she
was able to read even small prints.
DISCUSSION
Biotinidase deficiency remains underdiagnosed in
Pakistan. Biotinidase deficiency meets many of the
criteria for newborn screening; an inexpensive and
reliable screening test is available, untreated individuals
have high morbidity and mortality and effective and cost
effective/economical treatment is available.6 There are
no prior cases of BD reported from Pakistan but a
number of Pakistani children are reported in literature.7-9
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Table I: Clinical presentation and outcome of 4 patients with profound biotinidase deficiency.
Patient Age at onset Presenting Alopecia/ Ataxia Blood lactate Age at diagnosis Follow-up Outcome
symptoms skin rash (mmol/L) period
1 3 years Respiratory +/+ + 4.3 3 years 4 months 1 year Normal development and hearing.
4 months distress, stridor 5 months
2 18 months Seizures +/- - NA Confirmed 8 months Spastic paraplegia
diagnosis at 16 years
3 12 years Severe visual +/+ + 3.8 13 years 8 months Clinical improvement in visual acuity
3 months impairment and and regained independent ambulation
inability to walk 
4 7 years Visual impairment +/+ + 4.2 8 years 6 months 8 months Clinical improvement in visual acuity
6 months and inability to walk and regained independent ambulation
NA = Data not available.
Figure 1: (a-d) Patient 1. (e-h) Patient 3. (i-l) Paitent 4. 
(a,e,i) Alopecia, perioral and periorbital rashes before treatment. (b,f,j) Peri-
ungual rashes before treatment. (c,g,k) Resolved perioral, periorbital rashes
and growth of scalp hair after treatement. (d,h,l) Resolved periungual rashes
after treatment.
In Pakistan, due to high rate of consanguinity, incidence
of BD is expected to be high. In countries like Turkey
with high consanguinity incidence of BD is reported to be
1 in 14800.10 Incidence of BD in Pakistan needs to be
studied, because the treatment of BD is much more
cost-effective then the expense and resources needed
to support a blind, deaf or mentally challenged
individual. The presently described cases also showed
marked improvement following appropriate therapy with
reversal of visual handicap in one patient.
Hence, Pakistani physicians need to be made aware of
such a metabolic deficiencies which are both easily
diagnosable and easily treatable to avoid long-term
irreversible handicap.
REFERENCES
1. Wolf B. Worldwide survey of neonatal screening for biotinidase
deficiency. J Inherit Metab Dis 1991; 14:923-7.
2. Wolf B. The neurology of biotinidase deficiency. Mol Genet
Metab 2011; 104:27-34.
3. Wolf B. Clinical issues and frequent questions about biotinidase
deficiency. Mol Genet Metab 2010; 100:6-13.Epub 2010 Jan 11.
4. Wolf B, Grier RE, Allen RJ, Goodman SI, Kien CL, Parker WD,
et al. Phenotypic variation in biotinidase deficiency. J Pediatr
1983; 103:233-7.
5. Wolf B, Spencer R, Gleason T. Hearing loss is a common
feature of symptomatic children with profound biotinidase
deficiency. J Pediatr 2002; 140:242-6.
6. Wolf B, Heard GS, Jefferson LG, Proud VK, Nance WE,
Weissbecker KA. Clinical findings in four children with
biotinidase deficiency detected through a statewide neonatal
screening program. N Engl J Med 1985; 313:16-9.
7. Wastell HJ, Bartlett K, Dale G, Shein A. Biotinidase deficiency:
a survey of 10 cases. Arch Dis Child 1988; 63:1244-9.
8. Grunewald S, Champion MP, Leonard JV, Schaper J, Morris
AA. Biotinidase deficiency: a treatable leukoencephalopathy.
Neuropediatrics 2004; 35:211-6.
9. Mc Sweeney N, Grunewald S, Bhate S, Ganesan V, Chong
WK, Hemingway C. Two unusual clinical and radiological
presentations of biotinidase deficiency. Eur J Paediatr Neurol
2010; 14:535-8. Epub 2010 Feb 12.
10. Pomponio RJ, Coskun T, Demirkol M, Tokatli A, Ozalp I, Hüner
G, et al. Novel mutations cause biotinidase deficiency in
Turkish children. J Inherit Metab Dis 2000; 23:120-8.
Diagnosis, treatment and follow-up in four children with biotinidase deficiency from Pakistan
Journal of the College of Physicians and Surgeons Pakistan 2013, Vol. 23 (11): 823-825 825
